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HUMAN PLACENTA-DERIVED STEM CELL S (HPDSC) AUGMENT TRANS-
PLANTATION WITH UMBILICAL CORD BLOOD
Yu, L.C.1, Faleck, H.2, Johnson, K.2, Payne, D.2, Hariri, R.2 1 Children’s
Hospital/LSUHSC, New Orleans, LA; 2 Celgene, Warren, NJ
This is the first report of a patient treated in a single-arm,
non-randomized pilot study to assess the safety of human placenta-
derived stem cells (HPDSC) transplantation with partially- or
fully- HLA matched, related-donor umbilical cord blood (UCB)
for malignant or non-malignant disorders requiring stem cell trans-
plantation. HPDSC is being developed by Celgene Cellular Thera-
peutics (CCT) to augment the UCB stem cell graft. HPDSC is
obtained by CCT’s proprietary process involving perfusion of pla-
cental vasculature and is processed to remove red blood cells, non-vi-
able cells and tissue debris. HPDSC is enriched in CD341 cells and
other progenitor cell types. Non-clinical studies have shown that
augmenting aUCB transplant withHPDSC results in a higher likeli-
hood of successful engraftment and an earlier engraftment as com-
pared to UCB alone or HPDSC alone. It is hypothesized that the
infusion of HPDSC following UCB transplantation will improve
transplant outcome, shorten the time to neutrophil and/or platelet
engraftment and diminish serious complications of the transplant
procedure. The first patient is a 5 year old, 24 kg male with very
high risk ALL in first remission. The subject underwent standard
full ablative conditioning. GVHD prophylaxis consisted of steroids
and cyclosporine. The subject was transplanted with a UCB unit
(596.20  106 TNC, 73% post-thaw viability, 0.26% CD341) and
HPDSC unit (294  106 TNC, 63% post thaw viability, 0.85%
CD341) obtained from his HLA-matched sibling and processed/
stored by LifeBankUSA, a wholly owned subsidiary of Celgene
Corp. There were no clinically significant infusion reactions, and
to date there have been no HPDSC-related serious adverse events.
Myeloid engraftment occurred byDay117 and platelet engraftment
by Day170. There was no evidence of serious infection nor
aGVHD. Complete donor chimerism was evident by Day130.
The subject was discharged from the hospital on day 115. Subject
is disease-free for more than 6 months post-transplant and his im-
mune system is recovering as expected. Based upon this initial expe-
rience, infusion of HPDSC was safe and may have therapeutic
benefit in augmenting cord blood transplantation. Continuation of
the study is warranted.132
A HIGH INCIDENCE OF ACUTE GRAFT-VERSUS-HOST DISEASE IN
UNRELATED CORD BLOOD TRANSPLANTATION IN PAEDIATRIC
PATIENTS – A SINGLE CENTRE EXPERIENCE
Chan, L.A., Abdullah, W.A., Chong, L.A., Ariffin, H. University Malaya
Medical Centre, Kuala Lumpur, Malaysia
Introduction:Haematopoietic stem cell transplantation (HSCT)
is the treatment of choice for certain malignant and inherited disor-
ders in paediatric patients. The use of unrelated cord blood (UCB) as
a stem cell source presents advantages which include immediate
availability, less stringent HLA matching and less graft-versus-host
disease (GVHD). Grade II to IV aGVHD has been reported to be
between 14 to 36% in HLA 2/6 mismatched UCBT. We report
a much higher incidence of aGVHD.
Materials: From 1997 till 2008, singleUCB units from various in-
ternational cord blood banks were imported for 31 patients. Indica-
tions for transplantation included ALL in 9 pts, AML 4, JMML 3,
CML in CP 1, SAA 1, Thalassaemia 8 , Wiskott-Aldrich syndrome
2 and Osteopetrosis 3. Cord blood units were 3,4, 5 or 6 HLA
matched units for 1, 18, 9 and 3 recipients consecutively. Condition-
ing regimen for ALL included TBI and CY6 ATG6Thiotepa. Pa-
tients with AML received BU and CY6ATG while the majority of
non-malignant disorders were conditioned with BU1CY1ATG.
Prophylaxis against GVHD used cyclosporine(CSA) with low dose
MTX or prednisolone or CSA alone. Treatment of GVHD included
methyprednisolone, ATG, MMF and infliximab.
Results: The median age was 5 years (range 0.7–13 years) and
weight was 17.5 kg (5.56–50.2 kg). Median nucleated cell dose was
8.7  107/kg (range 2.6–29.3) while median CD341 cell dose was
2.6  105/kg (range 0.48–12.2). Four patients were early deaths
and not evaluable for engraftment. Twenty out of 27 pts (74%) expe-rienced neutrophil engraftment at a median of D25 (range 12–36)
and platelet.20K at a median of D46 (36–183) while primary graft
failure occurred in 7 pts (26%). AGVHD occurred in 19/20 pts with
clinical grades I, II, III and IV occurring in 1,7,7 and 4 pts respec-
tively. Of the 11 pts with grades III and IV aGVHD (55%), 3 were
alive while 8 succumbed to infection or multiorgan failure. Chronic
GVHD occurred in 3/13 evaluable pts where 1 was extensive. VOD
occurred in 9 pts. Mortality occurred in 17/31 pts (55%). Survival
was seen in 14 pts (45%) with follow up from 5–95 months.
Conclusion: We experienced a 95% incidence of aGVHD and
more than half of them were severe clinical grade III and IV which
directly contributed to mortality of patients.133
OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HCT) FROM UMBILICAL CORD BLOOD (UCB) UNITS IN PATIENTS
WITH MALIGNANT AND NON-MALIGNANT DISORDERS
Pawlowska, Bolotin, Mai-ton, Senitzer, Dagis, Wang, Zlotnicki, Forman,
Rosenthal City of Hope, Duarte, CA
HCT is a curative treatment option for high risk malignant and
non-malignant diseases. HLA-identical donors are the preferred
graft sources. Matched unrelated donors have been utilized success-
fully for the last two decades. However, in about 30% of all patients
neither an HLA-matched sibling nor a MUD donor is available; for
these patients UCB has become an acceptable stem cell source. UCB
offers several advantages: rapid availability, the possibility of using
HLA-mismatched units and a decreased risk of GVHD. We ana-
lyzed the treatment outcomes in patients who have undergone
HCT using UCB at City of Hope. 45 patients with malignant
(82%) and non-malignant (18%) hematological disorders received
46 HCT using allogeneic or autologous UCB from January 1,
1997 through June 31, 2007. 29 patients (66%) carried a diagnosis
of acute leukemia. 36 patients received single cord unit (including
2 autologous transplants), 10 patients received two UCB units.
80% of patients were alive at day 100. 1 year and estimated 5-year
overall survival (0S) was 53% (95% CI 38%–89%) and 43% (95%
CI 28%–64%) respectively with median follow up of patients alive
at date of analysis of 4.2 years. Estimated 5-year survival for single
(excluding autologous), double and autologous UCB transplant
was 44% (95% CI 27%–60%), 28% (95% CI 4%–59%) and 100%
respectively. Degree of HLA mismatch impacted OS – patients
receiving UCB mismatched at 0 or 1 loci had significantly better
5-year survival (61%, 95% CI 40%–77%) compared to patients
transplanted with 2 to 3 antigen mismatched units (17% 95% CI
4%–36%) p 5 0.005. Neutrophil engraftment occurred at median
26 days (89% of patients engrafted by day 53). The incidence and
time to platelet engraftment to 20K and 50K was 76% (median
50.5 days) and 67% (median 69 days) respectively. 62% of patients
receiving single UCB developed acute GVHD (44% grade 1–2;
18% grade 3–4). 23% of these patients developed chronic GVHD
(20% limited, 3% severe). All patients who received two UCB units
developed acute GVHD (80% grade 1–2, 20% grade 3–4; and later
chronic GVHD). 14 patients (30%) developed CMV infection (4
prior to day 30, 7 within days 30–100, 3 post day 100). 26% of pa-
tients had culture proven viral infections. In conclusion, for patients
with high risk disease lackingHLA-matched sibling donor, UCB can
offer a rapidly available alternative source of stem cells with trans-
plant outcomes comparable to the results achieved using matched
unrelated donors.LATE EFFECTS/QUALITY OF LIFE
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DIABETES MELLITUS (DM) AND HYPERTENSION (HTN) IN ADULT
AND PEDIATRIC SURVIVORS OF ALLOGENEIC HEMATOPOIETIC-CELL
TRANSPLANTATION (HCT)
Majhail, N.S., Challa, T.R., Mulrooney, D.A., Baker, K.S., Burns, L.J.
University of Minnesota, Minneapolis, MN
DM and HTN are frequent early complications of allogeneic
HCT; however, their long-term outcome is not well known. We
52 Poster Session-Iconducted a retrospective cohort study to describe the risk factors
and natural history of post-transplant DM and HTN. Consecutive
allogeneic HCT recipients from 2003–2005 were included in this
study if they had survived .1 year post-transplant and had not
received a previous HCT. DM and HTNwere defined by published
adult and pediatric guidelines. The final cohort consisted of 180
patients (adult [$18 years] 106, pediatric [\18 years] 74); themedian
age was 27 (range 0.2–69) years. BeforeHCT, 13%hadDM, 9%had
HTN, 18% smoked and 19% were obese. Pediatric patients were
less likely to have pre-transplant DM, HTN, smoking history or
high-risk disease and more likely to receive myeloablative (MA)
conditioning. MA conditioning (Cy 1 1320 cGy TBI 6 Flu) was
given to 66% recipients, remainder received non-MA conditioning
(Cy 1 Flu 1 200 cGy TBI). All patients are followed until at least
2 years post-HCT at our center; among these 1 year survivors, 156
(87%) were alive at 2 years. Acute or chronic graft-versus-host dis-
ease occurred in 118 (66%) patients; of these, 34% received cyclo-
sporine (CSA) for .12 months and 47% received prednisone for
.12 months. Within 2-years after HCT, 54 (30%) had DM while
126 (70%) had HTN. Rates were similar for adult (DM 30%,
HTN 68%) and pediatric (DM 30%, HTN 73%) recipients. At 2
years post-HCT, 12% had persistent DM while 39% had persistent
HTN. Increasing cumulative dose of corticosteroids increased the
likelihood of having persistentDM at 2 years post-transplant (no ste-
roids 7%, # 0.25 mg/kg/d 13%, .0.25 mg/kg/d 27%, p 5 0.02);
such an association was not observed for HTN. On multivariate
analyses, risk factors for DM included history of DM pre-HCT (rel-
ative risk [RR] 5.0 [95% CI, 2.8–8.9]) and prednisone exposure (RR
2.4 [1.3–4.5]), while no predictive factors for resolution of post-
HCT DM were identified. CSA exposure was the only risk factor
for post-HCT HTN (RR 1.6 [1.1–2.5]), while history of HTN
pre-HCT was predictive for persistent HTN beyond 2 years (RR
3.07 [1.1–8.3]). DM andHTN are frequent among survivors of adult
and pediatric allogeneic HCT and can persist for an extended period
of time after transplantation. Continued monitoring and treatment
of DM and HTN is necessary in HCT survivors, especially if
survivors have been exposed to corticosteroids.135
MORTALITY OF HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
ADMITTED TO A MEDICAL INTENSIVE CARE UNIT (MICU) AS PREDICTED
BY THE HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY
INDEX (HCTCI)
Miller, S.M., Rossetti, J., Sahovic, E., Hilton, C., Lister, J. The Western
Pennsylvania Cancer Institute, Pittsburgh, PA
Introduction: Severity of illness scores validated in the critical
care setting are known to underestimate mortality in cancer patients.
We evaluated theHematopoietic Cell TransplantationComorbidity
Index (HCTCI) score (Sorror et al) as a predictor of mortality in
HCT recipients requiring intensive care.
Methods: A retrospective review of HCT recipients transplanted
between January 1, 1997, and March 1, 2007 was preformed. The
HCTCI score was calculated for each patient at the time of admis-
sion to the MICU. The primary endpoint was defined as survival
for seven days from the time of discharge from the MICU. Co-
variates analyzed included age, sex, conditioning regimen, need for
mechanical ventilation, use of vasopressors, time from transplant
to MICU admission, HCT type, and absolute neutrophil count
(ANC) at the time of MICU admission.
Results: Seventy-four of 892 patients (8.3%) required MICU
care. Forty-two (57%) were males, 32 (43%) females and the median
age was 47 (range: 22–71). Twenty-three (31%) patients received
autologous, 26 (35%) matched related donor (MRD) and 25 (34%)
matched unrelated donor (MUD) HCT. Overall mortality was
72%. Using the Wilcoxon signed-rank test, the HCTCI score was
found to be highly predictive of mortality (p\0.0001). None of the
patients with an HCTCI score of $10 survived. Univariate analysis
identified transplant type [mortality: autologous 52%, MRD 73%,
MUD 88%; p 5 0.02], conditioning [mortality: myeloablative
91% versus non-myeloablative 57%; p5 0.002], mechanical ventila-
tion (MV): [mortality: MV n5 43, 79% versus noMV n5 31, 61%;
p5 0.0003], and ANC [mortality:\500 /mL 88%, ANC$ 500 /mL
60%; p5 0.01] as correlating with mortality. In multivariate analysis
only the HCTCI score remained significantly correlated withmortality (p 5 0.001) with a point estimate of the odds ratio of 2.8
(95% C.I. 1.5–5.3).
Conclusion:This retrospective study demonstrates the predictive
value of the HCTCI for mortality when calculated on admission to
the MICU at our institution. The HCTCI score is easily calculated
and readily applicable in the clinical setting. Prospective study of
the HCTCI is needed for validation of this tool as a predictor of
mortality on MICU admission.136
UTILITY OF THE PSYCHOSOCIAL ASSESSMENT OF CANDIDATES FOR
TRANSPLANTATION (PACT) SCALE IN ALLOGENEIC BMT
Foster, L.W.1, McLellan, L.J.2, Rybicki, L.A.2, Bolwell, B.J.2 1 Cleveland
State University, Cleveland, OH; 2 Cleveland Clinic, Cleveland, OH
The Psychosocial Assessment of Candidates for Transplantation
(PACT) scale was completed on 120 allogeneic BMT patients pre-
transplant, from 11/2003 to 6/2007. The PACT has 8 items, each
rated on a 5-point scale, and an initial and final rating independently
based on the rater’s overall impressions of the candidate’s accepta-
bility for transplant. This study assessed utility of the PACT scale
for psychosocial screening in allogeneic BMT. Examined were asso-
ciations of the eight PACT subscales and the final rating with
medical outcomes, post-transplant. Significant relationships (P #
0.05) between PACT subscales and medical outcomes are as follows:
better scores on compliance with medications and medical advice as-
sociates with lower in-hospital mortality, shorter length of stay and
readmission duration, and faster neutrophil and platelet engraft-
ment; better scores on drug/alcohol use associates with faster platelet
engraftment; better scores on family/support system availability and
on relevant knowledge and receptiveness to education associates with
decreased risk of mortality. The final rating score and medical
outcomes are not significantly related; however, study findings
underscore the prognostic value of the PACT subscales and, thus,
utility for screening of BMT candidates.137
ETHICAL REASONING ABOUT PATIENT ELIGIBILITY IN ALLOGENEIC BMT
BASED ON PSYCHOSOCIAL CRITERIA
Foster, L.W.1, McLellan, L.J.2, Rybicki, L.A.2, Bolwell, B.J.2 1 Cleveland
State University, Cleveland, OH; 2 Cleveland Clinic, Cleveland, OH
Chairpersons of hospital ethics committees (HEC) and BMT
clinicians were compared regarding willingness to proceed with
allogeneic BMTgiven select psychosocial risk factors. A self- admin-
istered questionnaire was sent to 62 HEC chairpersons at hospitals
with an accredited BMT Program; response rate was 37%. Items in-
cluded background information, followed by six case vignettes from
a 2006 national survey on which BMT physicians, nurses, and social
workers agreed not to proceedwith allogeneic BMTbased on the fol-
lowing risk factors: suicidal ideation; use of addictive, illicit drugs;
history of non-compliance; has no caregiver; is alcoholic; and has
mild dementia. Opinions regarding transplant differed on one case
only, patient with mild dementia; 27% of HEC chairpersons recom-
mended not proceeding with BMT, which was significantly lower
than nurses (68%, p\ 0.001), physicians (63.5%, p\ 0.001), and
social workers (51.9%, P5 0.05). That HEC chairpersons disagreed
with BMT clinicians in the case of mild dementia may suggest that
they view dementia patients as more deserving of consideration for
BMT than patients who have some element of choice in the psycho-
social risk factor. In general, qualitative data reveal patterns of infor-
mal ethical reasoning that suggest transplant decisions may be linked
to patient responsibility for the psychosocial risk factor as well as
medical benefit/outcome.138
AVASCULAR NECROSIS (AVN) IN SURVIVORS OF HEMATOPOIETIC-
CELL TRANSPLANTATION (HCT): A LARGE SINGLE INSTITUTION
STUDY
McAvoy, S., Mulrooney, D.A., Arora, M., Baker, K.S., Burns, L.J.,
Majhail, N.S. University of Minnesota, Minneapolis, MN
AVN is a debilitating complication of HCT. We describe a con-
temporary cohort of patients with AVN after HCT to describe its
